Panacea Life Sciences Holdings Inc · OTC:PLSH

Panacea Life Sciences — Exactus — Investor Presentation (April 2019)

17 slides from Panacea Life Sciences's investor presentation, Apr 1, 2019

  1. Slide 1: Hemp CBD From Seed

    HEMP CBD FROM SEED — GENETIC SCIENCESTARTS WITH THE SEED WE ARE*ALWAYS IN CONTROL OTCQB: EXDI April 2019

  2. Slide 2: Forward-Looking Statements

    STATEMENTS This presentation includes forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets for future development and/or otherwise are not statements of historical fact. These forward-looking statements are ba

  3. Slide 3: Defining Our Hemp Playing Field — Exactus' Mission Statement

    Defining Our “Hemp” Playing Field — Exactus’ Mission Statement MISSION STATEMENT * Our mission is to become the most trusted name in the CBD business. * Our focus is purely the pursuit of healthy products that are derived from hemp. We are committed to a hemp based future in which products are devel

  4. Slide 4: Corporate Overview

    CORPORATE OVERVIEW ] ZN Operating Goals Hemp-Based CBD Products * Private Label and Branded “Hemp Healthy®” Products Majority Interest in 200 Acre Industrial Hemp Farm Assisting Medical and Health-Care Professionals with Hemp Derived Education and Products * Pharmacy Sales of Hemp Derived Consumable

  5. Slide 5: USA Hemp/CBD Market Opportunity

    USA HEMP/CBD MARKET OPPORTUNITY $367M 2017 — Sales of $367M and 2018 — Hemp derived CBD expected to be >$500M in 2018* outpacing cannabis derived CBD ll The Brightfield Group estimates the total CBD market will be at ~$22B in 2022 Growth in specialty retailers will double in the same time frame to 2

  6. Slide 6: The Exactus Advantage

    THE EXACTUS ADVANTAGE ] HEMP! EAL HY so00m CBD Plus Master Development and Supply Agreement Hemp Healthy® Products * Partnered with Ceed2Med, our largest * Full spectrum whole plant extract used in all our shareholder, for dedicated supply of biomass, products genetics, isolate/distillate for brande

  7. Slide 7: Exclusive Manufacturing and Development Partnership

    EXCLUSIVE MANUFACTURING AND DEVELOPMENT PARTNERSHIP Multi year Master Supply and Development Agreement Premier pricing Attractive credit terms oO Seed genetics, farming, processing, manufacturing, testing ae and distribution expertise All Stages of Production to the highest cGMP, food grade standard

  8. Slide 8: Hemp Healthy Direct To Consumer Platform

    HEMPHEAL HY Direct To Consumer Platform a www.buyhempcbd.com PHEALTHY” * Full spectrum whole plant extract (entourage effect from full spectrum cannabidiol oil + pure 99% crystalline cannabidiol) * Trusted Quality Assurance: 3rd Party Lab Testing & Good Manufacturing Processes For All Of Our CBD Pro

  9. Slide 9: Seed to Sale Tracking

    SEED TO SALE TRACKING ell 4 —_®) Certified GMP @ Genetics Extraction a Cultivation (@ in a8 As Manufacturing Test and Analysi est and Analysis © Q (es Retailer Compliance (@ 4 bob Transportation Q fm Consumer

  10. Slide 10: Oregon CBD Seeds

    Oregon CBD Seeds * One of five companies globally with access to their genetics * 30 years of combined cannabis production and policy experience of its founders Seth and Eric Crawford Our farm in Oregon is located in the Illinois Valley, well known for its superior hemp growing topography Farming te

  11. Slide 11: Investment Highlights

    INVESTMENT HIGHLIGHTS \\___ Leading the development of and exceeding current oo industry standards Highest quality products on the market * Patent pending formulation technology * Patent focused si) A Healthcare and professional focused, “high-end” sales mall strategy * Premium pricing and margins D

  12. Slide 12: Management

    12 MANAGEMENT JONATHAN GILBERT EXECUTIVE CHAIRMAN Founder and CEO of Scythian Biosciences, Inc. from 2014 through May of 2018. Scythian Biosciences, Inc. is a publicly-traded research and development company focusing on the prevention and treatment of concussions and traumatic brain injury with its

  13. Slide 13: Board of Directors

    BOARD OF DIRECTORS KENNETH E. PUZDER Director Kenneth E. Puzder serves as Chief Financial Officer of Ceed2Med. In addition, from December of 2014 to the present, he has served as the co-founder, Managing Member, and CFO of the Lukens Group, LLC. From 2003 through 2006, he served as Chief Financial O

  14. Slide 14: Advisory Board

    ADVISORY BOARD EMILIANO ALO! PRESIDENT OF EXACTUS & SENIOR ADVISOR Co-founder of Ceed2Med, LLC Vice President, Strategic Development and Director, Strategic Development, GenCanna Global Agro-industrial Supply and Market Development Professional Co-sponsored research programs for Stevia and Aloe Vera

  15. Slide 15: 2019 Milestones

    2019 MILESTONES Majority ownership in 200 acre industrial Initiate FDA hemp farm. Acquired regulatory Complete FDA Hemp Healthy direct readiness regulatory Ql, 2019 to consumer platform. Q2, 2019 framework. Q3, 2019 readiness review. ceed2Med Qi, 2019 complete the Q2, 2019 Upon eligiity Q4, 2019 Dev

  16. Slide 16: OTCQB listed, planned NASDAQ uplisting with future public offering

    OTCQB listed, planned NASDAQ uplisting with future public offering Executed Master Product Development and Supply Agreement Full control over all aspects of the product lifecycle * Seed to final product tracking and accountability * Highest standards throughout the product lifecycle Majority ownersh

  17. Slide 17: From The Seed To The Final Product

    From The Seed To The Final Product Only The Highest Standards Leading The Way Raising The Bar For further information contact: PHILIP YOUNG, Chief Executive Officer Email pyoung@exactusinc.com Andrew Johnson, Chief Strategy Officer Email ajohnson@exactusinc.com

Exactus — Investor Presentation (April 2019) on 6ix